PTC Therapeutics (PTCT) announced that Sephience has been approved by the Japanese Ministry of Health, Labor and Welfare for the treatment of children and adults living with phenylketonuria. The label includes individuals of all ages and the full spectrum of disease severity. PTC will now engage in pricing discussions which are expected to conclude in Q1 2026, with launch occurring shortly thereafter.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PTCT:
- PTC Therapeutics: Strong Growth Potential Driven by R&D Expertise and Successful Sephience Launch
- Carvana initiated, Zscaler downgraded: Wall Street’s top analyst calls
- Cadrenal Therapeutics appoints Lee Golden to board of directors
- PTC Therapeutics downgraded to Sector Perform from Outperform at RBC Capital
- SanDisk Stock (SNDK) Jumps on S&P 500 Inclusion and Price Target Upgrades